Swedish manufacturer acquires Valneva facility

NorthX Bi­o­log­ics, a cell and gene ther­a­py man­u­fac­tur­ing and de­vel­op­ment out­fit based in Mat­fors, Swe­den, has ac­quired a fa­cil­i­ty from Val­ne­va.

As part of the deal, NorthX has se­cured Val­ne­va’s mul­ti­pur­pose fa­cil­i­ty in Stock­holm near Karolin­s­ka Uni­ver­si­ty Hos­pi­tal for an undis­closed amount. Ac­cord­ing to a re­lease, the 30 staff mem­bers who op­er­ate the fa­cil­i­ty will join NorthX, bring­ing with them ex­pe­ri­ence in man­u­fac­tur­ing Val­ne­va’s prod­ucts and work­ing on oth­er projects on a con­tract ba­sis. The move is ex­pect­ed to al­low NorthX to boost its man­u­fac­tur­ing ca­pa­bil­i­ties, qual­i­ty con­trol abil­i­ties and oth­er de­vel­op­ment work.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN